Jason Paris, MD
Allergy & Immunology · Livonia, MINPI 1376502096
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by GSK at 40.7% of the total. Reporting peaked in 2021 at $15,808 and has fallen 67.6% since, to $5,120 in 2025. Among allergy & immunology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 788 payments — averaging $55.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$18K
- AstraZeneca$15K
- Regeneron Healthcare Solutions, Inc.$2K
- Genentech USA, Inc.$2K
- Sanofi$1K
- Novartis$1K
- plus $5K from 27 others
Across 1 payment — averaging $22,666 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hoffmann-la Roche Limited$23K
What the payments were for
- Consulting fees$1,3503%
- Speaking & faculty fees$25,40058%
- Travel & lodging$1,0402%
- Food & beverage$15,91136%
- Education$2641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 146 | $17,879 |
| AstraZeneca | 166 | $14,677 |
| Regeneron Healthcare Solutions, Inc. | 92 | $2,154 |
| Genentech USA, Inc. | 19 | $1,627 |
| Sanofi | 66 | $1,362 |
| Novartis | 51 | $1,195 |
| CSL Behring | 68 | $1,025 |
| Amgen(2 entities) | 18 | $593 |
| Kaleo, Inc. | 28 | $508 |
| Aerin Medical Inc. | 4 | $473 |
| Optinose US, Inc. | 20 | $437 |
| Teva Pharmaceuticals USA, Inc. | 23 | $371 |
| Pfizer | 21 | $348 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $199 |
| Boehringer Ingelheim | 11 | $165 |
| AbbVie(2 entities) | 7 | $134 |
| Biocryst US Sales Co., LLC | 3 | $84 |
| Grifols USA, LLC | 4 | $79 |
| Merck | 4 | $77 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $77 |
| Octapharma USA, Inc. | 3 | $74 |
| Hospira, Inc. | 3 | $72 |
| Blueprint Medicines Corporation | 3 | $66 |
| Aimmune Therapeutics, Inc. | 3 | $55 |
| Organon | 4 | $48 |
| Jubilant Hollisterstier LLC | 2 | $38 |
| Bio Products Laboratory USA, Inc. | 2 | $26 |
| Eyevance Pharmaceuticals LLC | 2 | $25 |
| Lilly USA, LLC | 1 | $22 |
| LEO Pharma Inc. | 1 | $21 |
| Alk-abello, Inc | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| USWM, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$15,972
- AIRSUPRA$11,221
- XOLAIR$1,350
- DUPIXENT$236
- VIVAER STYLUS$158
- RHINAER STYLUS$158
- TEZSPIRE$131
- FASENRA$130
- NUCALA$122
How this compares
$43,965 in reported general payments places this provider in the 90th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 249 | $195,534 |
| Dupixent SyringeDupilumab | 13 | $45,567 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $31,851 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $18,215 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $17,119 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 40 | $10,460 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $10,096 |
| Montelukast Sodium | 249 | $4,398 |
| Ipratropium Bromide | 79 | $4,162 |
| Epinephrine | 25 | $4,159 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 13 | $3,664 |
| Azelastine Hcl | 105 | $3,402 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $3,277 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,548 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $17,879 | $227,385306 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $14,677 | $27,21550 claims |
| Hikma Pharmaceuticals USAEpinephrine | $18 | $4,15925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in Livonia
- Erica RidleyLivonia$2K
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Nicholas HartogGrand Rapids$575K
- Kathleen DassOak Park$446K
- Pulin PatelMount Clemens$431K
- Alan BaptistAnn Arbor$168K
- Mohsen NasirSaginaw$99K
- Abdul Husein BahrainwalaRoyal Oak$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.